A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study will research the side effects of pegaspargase (pronounced "peg-as-par-gase"); its
brand name is ONCASPAR® when it is used with another FDA-approved cancer treatment
(chemotherapy) drug called gemcitabine HCl (pronounced "gem-site-a-bean"; its brand name is
GEMZAR®.